Text this: Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non - small-cell lung cancer in Asia (IPASS)

 __   _      ___     _    _    _    _     _____   
| || | ||   / _ \\  | || | || | || | ||  / ____|| 
| '--' ||  / //\ \\ | || | || | || | || / //---`' 
| .--. || |  ___  ||| \\_/ || | \\_/ || \ \\___   
|_|| |_|| |_||  |_|| \____//   \____//   \_____|| 
`-`  `-`  `-`   `-`   `---`     `---`     `----`